EA - A Potential Cheap and High Impact Way to Reduce Covid in the UK this Winter by Lawrence Newport
The Nonlinear Library: EA Forum - A podcast by The Nonlinear Fund
Categories:
Link to original articleWelcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: A Potential Cheap and High Impact Way to Reduce Covid in the UK this Winter, published by Lawrence Newport on October 28, 2022 on The Effective Altruism Forum.Brief problem summary: Under current plans, millions of adults in the UK this winter will be unable to get a covid booster, even if they are willing to pay for it, because there will be no option for them to take the vaccine in the NHS rollout, and they will not be allowed to pay privately for a bivalent booster. That means overall population immunity will be lower and will lead to more covid cases than otherwise, which will increase the strains on NHS services this winter.This is an area in which EAs might have a potentially very large impact for small investment by creating a simple website to encourage people who would be willing to pay for a booster to give their email address. That list could then be used to convince Pfizer or another company to choose to make covid booster vaccines privately available in the UK, just as they will be in the US from January 2023 and as flu vaccines currently are in the UK.The IssuePfizer's bivalent vaccine (vaccinating against both the original covid and Omicron variants) is being rolled out in the UK via the NHS. The original vaccination and initial booster programme in the UK started with the most vulnerable and frontline health workers, and expanded down risk profiles until all adults in the UK had been offered the opportunity to have a vaccine and a booster.However, the plan is more limited for Pfizer's bivalent booster vaccine. This winter the UK has opted for a policy which will see only the most vulnerable and frontline health workers being offered the vaccine. Unlike flu vaccines, where anyone can walk into a pharmacy and pay a small fee for a flu vaccine if they are not entitled to a free vaccine, that will not be possible for covid boosters. To put this in perspective:Number of people who were vaccinated in the UK:First dose: ~54MSecond dose: ~51MBooster: ~40MThose to be offered a bivalent booster:Estimated total to be offered a bivalent booster: 26MIn other words, even with 100% uptake of the booster, this leaves a potentially willing 28M adults without even the option of a booster from the NHS or privately.It is of course entirely right to start rollouts to the most vulnerable – and to expand those groups as widely as possible. The issue is that there is no option, other than travel to the US, for the majority of willing UK adults to receive a bivalent vaccine. It is clear that, all other things being equal, more population immunity is better. Waning immunity in millions of UK adults will reduce ongoing pandemic mitigation. That is particularly a problem when the winter burden of covid and flu on the NHS is expected to be large, impairing outcomes for treatment of other illness.I understand that there is no longer any shortage of vaccines; vaccine takeup in the UK has been lower than expected. Although it might be better for the NHS to provide boosters free of charge to all who want them, the Government has decided not to do that. But in any case, it would be strictly better for all concerned, including those who do not get a booster, if the number of covid cases were reduced by making it possible for people to pay a modest fee for a booster if they are not entitled to a free one.Pfizer has stated that it will be selling vaccines in the US from 2023 when the US Government stops providing them free of charge. In the UK flu vaccines are sold privately and are administered in pharmacies by trained staff members. Currently, there is no public argument or expectation that the bivalent vaccine should be available for purchase in the UK.However, there may be a solution. Based on confidential discussions with sources that I cannot name but who I believe ...
